Suppr
超能文献

未感染过新冠病毒的个体接种不同新冠疫苗后的反应原性及抗受体结合域刺突蛋白1（RBD-S1）IgG浓度峰值

Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines.

作者信息

Milevoj Kopcinovic Lara, Unic Adriana, Nikolac Gabaj Nora, Miler Marijana, Vrtaric Alen, Bozovic Marija, Stefanovic Mario

机构信息

Department of Clinical Chemistry, Sestre Milosrdnice University Hospital Center, Zagreb, Croatia.

Faculty of Pharmacy and Biochemistry, University of Zagreb, Zagreb, Croatia.

出版信息

Lab Med. 2024 Mar 7;55(2):162-168. doi: 10.1093/labmed/lmad044.

DOI:10.1093/labmed/lmad044

PMID:37294928

Abstract

OBJECTIVE

To investigate the association of immune response with vaccination adverse effects at peak anti-receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria.

METHODS

Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested.

RESULTS

Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups.

CONCLUSIONS

No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.

摘要

目的

研究在全程接种辉瑞疫苗（Comirnaty）、莫德纳疫苗（Spikevax）或阿斯利康疫苗（Vaxzevria）后，抗受体结合域刺突亚基1（anti-RBDS1）IgG达到峰值时免疫反应与疫苗不良反应之间的关联。

方法

对接种辉瑞疫苗、莫德纳疫苗和阿斯利康疫苗的健康成年人测定接种后anti-RBDS1 IgG浓度。测试接种后反应原性与抗体反应峰值之间的关联。

结果

与阿斯利康疫苗组相比，辉瑞疫苗组和莫德纳疫苗组的anti-RBDS1 IgG值显著更高（P < 0.001）。在辉瑞疫苗组和莫德纳疫苗组中，发热和肌肉疼痛被发现是抗RBDS1 IgG峰值的显著独立预测因素（分别为P = 0.03和P = 0.02）。经协变量调整的多变量模型显示，在辉瑞疫苗组、莫德纳疫苗组和阿斯利康疫苗组中，未发现反应原性与抗体浓度峰值之间存在关联。